Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icanbelimod - Suzhou Connect Biopharmaceuticals

Drug Profile

Icanbelimod - Suzhou Connect Biopharmaceuticals

Alternative Names: CBP-307

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Amines; Anti-inflammatories; Carboxylic acids; Cyclobutanes; Fluorobenzenes; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Ulcerative colitis

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • Phase I Autoimmune disorders
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO, Capsule)
  • 01 Jun 2023 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by Connect Biopharma
  • 10 Nov 2022 Suzhou Connect Biopharmaceuticals completes a phase-II trial in Ulcerative colitis in Ukraine, USA, China, Pakistan (PO) (NCT04700449)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top